# Cancer Control (93.399)

Source: https://welltoldgrants.com/programs/93-399-cancer-control/  
Publisher: Well Told Grants. Data: USAspending.gov and Grants.gov, updated November 7, 2026.

Cancer Control is run by Department of Health and Human Services. From fiscal 2021 to 2025 it awarded $814 million in 113 grants, about $7.2 million per award.

## Objectives

To reduce cancer risk, incidence, morbidity, and mortality and enhance quality of life in cancer survivors through an orderly sequence from research on interventions and their impact in defined populations to the broad, systematic application of the research results through dissemination and diffusion strategies. Primary emphasis is on the inclusion of cancer prevention and control intervention(s) in any proposed study. Cancer Prevention and Cancer Control research studies are classified into one of five phases: (1) Hypothesis development; (2) methods development and testing; (3) controlled intervention trials to establish cause-and-effect relationships; (4) research in defined populations; and (5) demonstration and implementation studies. Primary interests are in research on cancer control interventions in Phases 2 through 5, and on cancer prevention research in all phases. Cancer Prevention and Control programs include those in the following areas: (1) cancer epidemiology; (2) cancer communications; (3) nutrition, diet, and physical activity; (4) screening and early detection in health care delivery; (5) biobehavioral mechanisms; (6) tobacco control; (7) health disparities research; (8) supportive care and survivorship; (9) health services and outcomes research; and (10) surveillance research. Cancer Control uses Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs to engage domestic small business concerns in federal research and development that has potential for commercialization. The goals of the SBIR & STTR Programs are to stimulate technological innovation, increase private-sector commercialization of federal research and development, increase small business participation in federally funded research and development, and foster participation by socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation. The STTR Program requires the small business concern to formally collaborate with a research institution in Phase I and Phase II of the program.

## Funding by fiscal year

| Year | Amount | Awards |
|---|---|---|
| 2021 | $145 million | 74 |
| 2022 | $163 million | 84 |
| 2023 | $167 million | 87 |
| 2024 | $167 million | 90 |
| 2025 | $172 million | 93 |

## Largest recipients

| Recipient | State | Amount |
|---|---|---|
| Ecog-Acrin Medical Research Foundation, Inc. | Pennsylvania | $87.9 million |
| NRG Oncology Foundation Inc | Pennsylvania | $54.3 million |
| Alliance NCTN Foundation | Illinois | $50.2 million |
| Oregon Health & Science University | Oregon | $34.4 million |
| University of Rochester | New York | $29.8 million |
| Public Health Institute | California | $22.7 million |
| Fred Hutchinson Cancer Center | Washington | $22.4 million |
| Healthpartners Institute | Minnesota | $19.7 million |
| Wake Forest University Health Sciences | North Carolina | $19.3 million |
| Kaiser Foundation Hospitals | California | $19.0 million |
| Decatur Memorial Hospital | Illinois | $17.8 million |
| Trinity Health-Michigan | Michigan | $16.0 million |
| Spartanburg Regional Health Services District, Inc. | South Carolina | $15.2 million |
| Southeast Clinical Oncology Research Consortium | North Carolina | $13.9 million |
| Marshfield Clinic, Inc. | Wisconsin | $13.9 million |
| Swedish Health Services | Washington | $13.3 million |
| Louisiana State University Health Sciences Center New Orleans | Louisiana | $13.1 million |
| Corewell Health | Michigan | $11.4 million |
| Northwestern University | Illinois | $11.3 million |
| The Carle Foundation | Illinois | $11.2 million |

## Open opportunities

- [Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-370-ethical-legal-and-social-implications-elsi-small-research/), closes November 16, 2026
- [Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-369-ethical-legal-and-social-implications-elsi-exploratory/), closes November 18, 2026
- [Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-371-ethical-legal-and-social-implications-elsi-research-r01/), closes November 18, 2026
- [Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)](https://welltoldgrants.com/grants/par-24-214-academic-research-enhancement-award-area-for-undergraduate/), closes January 7, 2027
- [Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)](https://welltoldgrants.com/grants/par-25-098-interventions-to-expand-cancer-screening-and-preventive/), closes January 7, 2027
- [Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)](https://welltoldgrants.com/grants/par-25-167-cancer-prevention-and-control-clinical-trials-grant-program/), closes January 7, 2027
- [National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)](https://welltoldgrants.com/grants/par-25-081-national-cancer-institute-s-investigator-initiated-early/), closes January 7, 2027
- [Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-256-developing-novel-theory-and-methods-for-understanding-the/), closes January 7, 2027
- [Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-379-intervention-research-to-improve-native-american-health-r01/), closes January 7, 2027
- [Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-28-062-cancer-advancement-through-partnerships-in-research-and/), closes January 25, 2027
- [Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/rfa-ca-28-013-carcinogen-hazard-assessment-monographs-program-champ-r01/), closes February 9, 2027
- [Risk and Protective Factors of Family Health and Family Level Interventions (R01 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-317-risk-and-protective-factors-of-family-health-and/), closes March 6, 2027
- [Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities (R01, Clinical Trial Required)](https://welltoldgrants.com/grants/par-26-001-screening-brief-intervention-and-referral-to-treatment-or/), closes May 7, 2027
- [Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-24-254-change-of-recipient-organization-type-7-parent-clinical/), closes July 12, 2027
- [Successor-in-Interest (Type 6 Parent Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-24-253-successor-in-interest-type-6-parent-clinical-trial/), closes July 17, 2027
- [NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/pa-25-080-nih-support-for-conferences-and-scientific-meetings-parent/), closes September 7, 2027
- [Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional)](https://welltoldgrants.com/grants/par-24-330-interventions-to-reduce-sleep-health-disparities-r01/), closes September 7, 2027
- [Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)](https://welltoldgrants.com/grants/rfa-ca-27-019-early-stage-development-of-informatics-technologies-for/), closes October 19, 2027
- [Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)](https://welltoldgrants.com/grants/par-25-103-cancer-prevention-and-control-clinical-trials-planning-grant/), closes October 25, 2027
- [Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)](https://welltoldgrants.com/grants/par-25-104-cancer-prevention-and-control-clinical-trials-planning-grant/), closes October 25, 2027
- [Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)](https://welltoldgrants.com/grants/par-27-078-research-enhancement-award-program-reap-for-health/), closes October 25, 2027
- [Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-043-mechanisms-that-impact-cancer-risk-after-bariatric-surgery/), closes January 7, 2028
- [Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-044-mechanisms-that-impact-cancer-risk-after-bariatric-surgery/), closes January 7, 2028
- [Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-144-dissemination-and-implementation-research-in-health-r01/), closes January 7, 2028
- [Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-233-dissemination-and-implementation-research-in-health-r03/), closes January 7, 2028
- [Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-143-dissemination-and-implementation-research-in-health-r21/), closes January 7, 2028
- [Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-25-172-modular-r01s-in-cancer-control-and-population-sciences/), closes January 7, 2028
- [Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)](https://welltoldgrants.com/grants/par-25-148-academic-research-enhancement-award-area-for-undergraduate/), closes January 7, 2028
- [The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional)](https://welltoldgrants.com/grants/par-25-292-the-role-of-work-in-health-disparities-in/), closes January 7, 2028
- [Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-134-academic-research-enhancement-award-area-for-undergraduate/), closes January 7, 2028
- [Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)](https://welltoldgrants.com/grants/par-25-299-interventions-to-address-disparities-in-liver-diseases-and/), closes January 7, 2028
- [Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-298-research-enhancement-award-program-reap-for-health/), closes January 7, 2028
- [Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-321-exploratory-developmental-bioengineering-research-grants/), closes January 7, 2028
- [Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-346-exploratory-developmental-bioengineering-research-grants/), closes January 7, 2028
- [NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/pa-25-304-nih-exploratory-developmental-research-project-grant-parent/), closes January 7, 2028
- [NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)](https://welltoldgrants.com/grants/pa-25-306-nih-exploratory-developmental-research-project-grant-parent/), closes January 7, 2028
- [NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/pa-25-301-nih-research-project-grant-parent-r01-clinical-trial/), closes January 7, 2028
- [Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)](https://welltoldgrants.com/grants/pa-25-168-ruth-l-kirschstein-national-research-service-award-nrsa/), closes May 4, 2028
- [Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-25-253-exploratory-grants-in-cancer-control-r21-clinical-trial/), closes September 7, 2028
- [Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 eSubmission Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-324-method-to-extend-research-in-time-merit-award/), closes September 7, 2028
- [Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-26-001-administrative-supplements-to-existing-nih-grants-and/), closes November 30, 2028
- [NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-27-051-nih-brain-development-cohorts-nbdc-and-population-assessment/), closes April 17, 2029
- [NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-26-002-nih-collaborative-international-research-project-parent-pf5/), closes May 7, 2029
- [NIH Research Program Projects (Parent P01 Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-27-061-nih-research-program-projects-parent-p01-clinical-trial/), closes May 25, 2029
- [Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)](https://welltoldgrants.com/grants/rfa-ai-27-018-implementation-science-to-advance-hiv-prevention-treatment/), closes June 20, 2029
- [Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-27-072-bioengineering-research-grants-brg-r01-clinical-trial/), closes July 5, 2029
- [NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-27-088-nci-research-specialist-award-for-core-and-laboratory/), closes not stated
- [Implementation and Evaluation of Databases to Examine AIDS](https://welltoldgrants.com/grants/rfa-ai-28-025-implementation-and-evaluation-of-databases-to-examine-aids/), closes not stated
- [Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)](https://welltoldgrants.com/grants/rfa-ca-28-003-advanced-development-and-sustainment-of-informatics/), closes not stated
- [Investigator-Focused Award (Parent R35)](https://welltoldgrants.com/grants/par-28-037-investigator-focused-award-parent-r35/), closes not stated